Nuwellis Announces Pricing of $2.7 Million Public Offering

Stock Information for Daxor Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Daxor Corporation

Nuwellis, Inc. Announces First Quarter 2024 Financial Results
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
Nuwellis Announces Closing of $2.7 Million Public Offering
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.